Abstract
Stroke is the third common cause of death and the most common cause of adult disability. Approximately 80% of all strokes are ischemic (brain infarction). The only approved acute therapy is intravenous thrombolysis with tissue plasminogen activator within 3 h of symptom onset but only a small percentage of all ischemic stroke patients can receive this therapy. Therefore, novel therapeutic approaches directed at the pathophysiological mechanisms involved in ischemic brain injury are urgently needed. To this end several experimental stroke models were developed. These models are indispensable for understanding the pathophysiology of brain ischemia and to develop novel drugs and investigative methodology. This review considers the most commonly used ischemic stroke models (including preconditioning models) in rodents emphasizing their advantages and disadvantages. Since none of the models can perfectly simulate human stroke, researchers must interpret experimental findings carefully.
Keywords: Rat, mouse, infarction, brain, ischemia, therapy, ischemic tolerance, magnetic resonance imaging, preconditioning
Current Pharmaceutical Design
Title: Rodent Models of Ischemic Stroke: A Useful Tool for Stroke Drug Development
Volume: 14 Issue: 4
Author(s): Aysan Durukan, Daniel Strbian and Turgut Tatlisumak
Affiliation:
Keywords: Rat, mouse, infarction, brain, ischemia, therapy, ischemic tolerance, magnetic resonance imaging, preconditioning
Abstract: Stroke is the third common cause of death and the most common cause of adult disability. Approximately 80% of all strokes are ischemic (brain infarction). The only approved acute therapy is intravenous thrombolysis with tissue plasminogen activator within 3 h of symptom onset but only a small percentage of all ischemic stroke patients can receive this therapy. Therefore, novel therapeutic approaches directed at the pathophysiological mechanisms involved in ischemic brain injury are urgently needed. To this end several experimental stroke models were developed. These models are indispensable for understanding the pathophysiology of brain ischemia and to develop novel drugs and investigative methodology. This review considers the most commonly used ischemic stroke models (including preconditioning models) in rodents emphasizing their advantages and disadvantages. Since none of the models can perfectly simulate human stroke, researchers must interpret experimental findings carefully.
Export Options
About this article
Cite this article as:
Durukan Aysan, Strbian Daniel and Tatlisumak Turgut, Rodent Models of Ischemic Stroke: A Useful Tool for Stroke Drug Development, Current Pharmaceutical Design 2008; 14 (4) . https://dx.doi.org/10.2174/138161208783497688
DOI https://dx.doi.org/10.2174/138161208783497688 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Early Ischemic Blood Brain Barrier Damage: A Potential Indicator for Hemorrhagic Transformation Following Tissue Plasminogen Activator (tPA) Thrombolysis?
Current Neurovascular Research Infringement of the Barriers of Cancer Via Dietary Phytoconstituents Capsaicin Through Novel Drug Delivery System
Current Drug Delivery Pharmacological Therapy of Cushings Syndrome: Drugs and Indications
Mini-Reviews in Medicinal Chemistry Stroke: Molecular Mechanisms and Potential Targets for Treatment
Current Molecular Medicine Silimarin and Cancer
Anti-Cancer Agents in Medicinal Chemistry Do Not Say Ever Never More: The Ins and Outs of Antiangiogenic Therapies
Current Pharmaceutical Design Designed Multiple Ligands: Basic Research vs Clinical Outcomes
Current Medicinal Chemistry Combined Treatment Fkt-Botulinum Toxin Type A (Btx-A) in Patients with Strumpell-Lorrain Disease
Current Pharmaceutical Design Microglial Activation as a Compelling Target for Treating Acute Traumatic Brain Injury
Current Medicinal Chemistry Saxagliptin: A New Drug for the Treatment of Type 2 Diabetes
Mini-Reviews in Medicinal Chemistry Nutritional Antioxidants and Adaptive Cell Responses: An Update
Current Molecular Medicine Exosomes Harnessed as Nanocarriers for Cancer Therapy - Current Status and Potential for Future Clinical Applications
Current Molecular Medicine How to Keep Oxidative Stress Under Control?
Current Nutrition & Food Science Neuropsychiatric Systemic Lupus Erythematosus
Current Neuropharmacology New Molecular Targets in the Treatment of NSCLC
Current Pharmaceutical Design Drug Discovery in Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Thiol Proteases: Inhibitors and Potential Therapeutic Targets
Current Medicinal Chemistry Design and Development of a Novel Supportive Care Product for the Treatment of Sialorrhea in Parkinson’s Disease
Current Topics in Medicinal Chemistry Clearance of Amyloid-β Peptide Across the Choroid Plexus in Alzheimer's Disease
Current Aging Science Brain Proton Magnetic Resonance Spectroscopy: A Review of Main Metabolites and its Clinical Applications in Gliomas
Current Molecular Imaging (Discontinued)